Pfizer Bets On Monthly GLP-1 Obesity Drug To Reshape Growth Story
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…
Eli Lilly Soared by 39% in 2025, but Here’s Another Healthcare Stock to Buy in 2026
Eli Lilly’s (NYSE: LLY) share price jumped 39% in 2025, driven by investors eager to benefit from the…
Japan’s Shionogi boosts ViiV stake in $2.13 billion deal as Pfizer exits
Jan 20 (Reuters) – Japan’s Shionogi & Co said on Tuesday it ​would pay $2.13 billion for new…
Should You Buy Pfizer While It’s Under $30?
Pfizer has been struggling for several years. The company’s pipeline could help it turn things around. It also…
Where Will Pfizer Be in 5 Years?
Pfizer’s stock soared during the coronavirus pandemic because of its COVID-19 vaccine. The world has learned to live…
Better Buy in 2026: Pfizer or Eli Lilly?
Eli Lilly has been a dominant force in the GLP-1 market, and that looks set to continue. Pfizer’s…
Pfizer, YaoPharma sign $150M GLP-1 obesity drug collaboration
Key Terms phase 1 medical Phase 1 is the first stage of testing…
Ireland has two economies, one bourgeois, one proletarian. Both have problems – The Irish Times
How do you know our rulers are spoofing? A cynic might say the tell is that they have…
Which Healthcare Giant Is the Better Bet?
Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong…
2 No-Brainer Healthcare Stocks to Buy Now
Pfizer’s acquisition of obesity drugmaker Metsera positions the pharmaceutical giant to compete in a market expected to reach…
Deal With Eli Lilly Propels Founder Of Korean Biotech Firm Into Billionaire Ranks
A $2.6 billion licensing and joint research deal with Eli Lilly boosted shares of South Korean biotech company…
How Recent Moves Are Rewriting the Story for Pfizer
Pfizer’s fair value estimate has inched upward recently, rising from $28.86 to $29.08 per share. The discount rate…